Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study

Authors

Torbjörn Åkerfeldt (ORCID: https://orcid.org/0000-0003-0214-596X)
Håkan Arheden (ORCID: https://orcid.org/0000-0002-6124-3159)
Anders Själander (ORCID: https://orcid.org/0000-0001-9422-1186)
Annica Ravn‐Fischer (ORCID: https://orcid.org/0000-0003-2585-1592)
Anna Björkenheim (ORCID: https://orcid.org/0000-0002-4288-3310)
Magnus Janzon (ORCID: https://orcid.org/0000-0002-9375-5087)
Lars Wallentin (ORCID: https://orcid.org/0000-0003-0378-6531)
Ziad Hijazi (ORCID: https://orcid.org/0000-0002-7420-743X)
Jonas Oldgren (ORCID: https://orcid.org/0000-0002-9969-3921)
Viveka Frykman (ORCID: https://orcid.org/0000-0002-0376-8133)
Henrik Renlund (ORCID: https://orcid.org/0000-0002-2141-6086)

Institutions

Linköping University (SE)
Uppsala University (SE)
Karolinska University Hospital (SE)
Uppsala University Hospital (SE)
Lund University (SE)
Örebro University (SE)
Sahlgrenska University Hospital (SE)
Danderyds sjukhus (SE)
Karolinska Institutet (SE)
Skåne University Hospital (SE)
Umeå University (SE)

Publication Details

Journal: Circulation
Published: 2025-08-30
DOI: https://doi.org/10.1161/circulationaha.125.076725
Citations: 3
Primary Topic: Atrial Fibrillation Management and Outcomes
Type: article
Field-Weighted Citation Impact: 4.16

Funders

Amgen
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
AstraZeneca
Sanofi
Regeneron Pharmaceuticals
Amarin Corporation
Stiftelsen för Strategisk Forskning
Svenska Sällskapet för Medicinsk Forskning
Hjärt-Lungfonden
Novo Nordisk
Vetenskapsrådet
Akademiska Sjukhuset
Uppsala Universitet
Roche Diagnostics

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study

Torbjörn Åkerfeldt, Håkan Arheden, Anders Själander, Annica Ravn‐Fischer et al.

Aug 30, 2025

3 citations

Circulation

Atrial Fibrillation Management and Outcomes

4.16

article

Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study

Torbjörn Åkerfeldt, Håkan Arheden, Anders Själander, Annica Ravn‐Fischer, Anna Björkenheim, Magnus Janzon, Lars Wallentin, Ziad Hijazi, Jonas Oldgren, Viveka Frykman, Henrik Renlund

August 30, 2025article en

3 citations

Abstract

No abstract available for this paper.

CirculationVol. 152(21)

Linköping University (SE), Uppsala University (SE), Karolinska University Hospital (SE), Uppsala University Hospital (SE), Lund University (SE), Örebro University (SE), Sahlgrenska University Hospital (SE), Danderyds sjukhus (SE), Karolinska Institutet (SE), Skåne University Hospital (SE), Umeå University (SE)

Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Regeneron Pharmaceuticals, Amarin Corporation, Stiftelsen för Strategisk Forskning, Svenska Sällskapet för Medicinsk Forskning, Hjärt-Lungfonden, Novo Nordisk, Vetenskapsrådet, Akademiska Sjukhuset, Uppsala Universitet, Roche Diagnostics

Openalex Percentile: Top 5%

Atrial Fibrillation Management and Outcomes

4.16

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.